Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05767034 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 381
- Enrollment target
NCT05767034 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 381 participants.
The verdict
NCT05767034, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 381 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
Interventions
- DRUG Secukinumab 300 mg
- DRUG Secukinumab 150 mg
- OTHER Placebo to secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2026-02-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05767034
The ClinicalTrials.gov registry entry for NCT05767034 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Secukinumab 300 mg is the first listed.
NCT05767034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05767034 about?
NCT05767034 is a clinical study titled "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)". The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
What is the current status of trial NCT05767034?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2023-03-22. Estimated completion is 2026-02-16.
What interventions are being tested in trial NCT05767034?
The interventions under investigation include: Secukinumab 300 mg (DRUG), Secukinumab 150 mg (DRUG), Placebo to secukinumab (OTHER).
Who is sponsoring clinical trial NCT05767034?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.